Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Naurex Inc. maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action, which is located within 1 distinct art unit. This indicates a focused area of technical inquiry for the company's active applications.
The prosecution is conducted by 1 distinct examiner, CHIHYI NMN LEE. This individual is the busiest examiner for the portfolio, responsible for 1 busiest examiner pending action. Because the company only has 1 pending office action, the workload is entirely concentrated under the 1 distinct examiner. Practitioners should note that the 1 busiest examiner pending action constitutes the full extent of the company's current prosecution activity. The involvement of the 1 distinct art unit suggests that the company's current patent filings are not diversified across multiple examination groups. This results in a prosecution profile where the outcome of the pending office action is tied to the 1 distinct examiner's review.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, CHIHYI NMN | 1 | 34.1% | +61.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17621907 | SOLID FORMS OF TERT-BUTYL (S)-2((2S,3R)-1-AMINO-3-HYDROXY-1-OXOBU TAN-2-YL)-1-OXO-2, 5-DIAZASPIRO [3.4] OCTAN E-5-CARBOXYLATE AND METHODS OF PREPARING THEM | LEE, CHIHYI NMN | 34d |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17621907 | SOLID FORMS OF TERT-BUTYL (S)-2((2S,3R)-1-AMINO-3-HYDROXY-1-OXOBU TAN-2-YL)-1-OXO-2, 5-DIAZASPIRO [3.4] OCTAN E-5-CARBOXYLATE AND METHODS OF PREPARING THEM | LEE, CHIHYI NMN | 1628 | §112 | Final Rejection | 34d | Pending | Dec 22, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNaurex Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Chihyi Nmn Lee has the most, with 1 of Naurex Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.